U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H15NO
Molecular Weight 165.2322
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALSACLIDINE

SMILES

C#CCO[C@H]1CN2CCC1CC2

InChI

InChIKey=XVFJONKUSLSKSW-JTQLQIEISA-N
InChI=1S/C10H15NO/c1-2-7-12-10-8-11-5-3-9(10)4-6-11/h1,9-10H,3-8H2/t10-/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H15NO
Molecular Weight 165.2322
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Talsaclidine (WAL-2014) is a selective full agonist of M1 muscarinic receptor, having partial agonist activity on the M2 and M3 subtypes (with no in vivo consequences). The general receptor profile of talsaclidine demonstrates a nearly specific interaction with muscarinic receptors, having only weak binding affinity for alpha1- and nicotinic receptors. The drug is being tested in phase III of clinical trials for the treatment of Alzheimer's disease.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
18.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.7 ng/mL
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALSACLIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
730 ng/mL
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALSACLIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12 ng × h/mL
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALSACLIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4500 ng × h/mL
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALSACLIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
99%
TALSACLIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
2003
Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling.
2004 Jul 15
Zinc uptake is mediated by M1 muscarinic acetylcholine receptors in differentiated SK-SH-SY5Y cells.
2006 Feb
Patents

Sample Use Guides

Talsaclidine is administered orally at a dose of 24 mg, three times a day.
Route of Administration: Oral
In Vitro Use Guide
Isolated tracheal muscle from guinea-pigs was incubated with 1-3000 uM of talsaclidine to test the muscarinic receptor agonism.
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:52:03 GMT 2023
Edited
by admin
on Fri Dec 15 18:52:03 GMT 2023
Record UNII
1O8VSL798T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TALSACLIDINE
INN   WHO-DD  
INN  
Official Name English
talsaclidine [INN]
Common Name English
Talsaclidine [WHO-DD]
Common Name English
3-(2-PROPYNYLOXY)-1-AZABICYCLO(2.2.2)OCTANE, (R)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C47796
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
Code System Code Type Description
FDA UNII
1O8VSL798T
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
PRIMARY
NCI_THESAURUS
C96885
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
PRIMARY
SMS_ID
100000083228
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
PRIMARY
EVMPD
SUB10814MIG
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
PRIMARY
INN
7270
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
PRIMARY
DRUG BANK
DB12287
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
PRIMARY
ChEMBL
CHEMBL2111051
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
PRIMARY
WIKIPEDIA
Talsaclidine
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
PRIMARY
CAS
147025-53-4
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
PRIMARY
PUBCHEM
71792
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
PRIMARY
EPA CompTox
DTXSID20163565
Created by admin on Fri Dec 15 18:52:03 GMT 2023 , Edited by admin on Fri Dec 15 18:52:03 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
TARGET->PARTIAL AGONIST
TARGET->PARTIAL AGONIST
Related Record Type Details
ACTIVE MOIETY